PROCEPT BioRobotics Corp. Hits New 52-Week Low at $34.05

PROCEPT BioRobotics Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 34.05 as of October 1, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop by 49.45% over the past year, contrasting sharply with the S&P 500's performance of 16.09% during the same period.
Despite the recent price drop, PROCEPT BioRobotics has reported positive results for the last seven consecutive quarters. However, the company remains in a challenging financial position, with a negative return on equity of -21.80% and a debt-to-equity ratio of -0.65. The stock's price-to-book ratio stands at 5.61, indicating a premium valuation relative to its book value.

The company has also faced a negative EBITDA, reflecting ongoing financial pressures. With institutional holdings at 100%, PROCEPT BioRobotics is under the scrutiny of investors who typically have the resources to analyze the company's fundamentals more thoroughly. Overall, the stock's performance has been below par in both the long and short term, raising questions about its market position moving forward.